Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...
Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...
Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and ...
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vera Therapeutics (VERA – Research Report), ...
Rhythm Pharmaceuticals (NASDAQ:RYTM) has reported a robust first quarter in 2024, with a focus on the commercial execution of ...
In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against other worst high-risk high-reward growth stocks to buy. Is the Tariff Solution ...
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
In a recent transaction, Joseph Shulman, the Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), sold 10,468 ...
German airline Lufthansa's air freight business said on Friday it is experiencing an increase in demand for pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results